NCT00593944View on ClinicalTrials.gov

Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Chronic Lymphocytic Leukemia
Interventions
BIOLOGICAL

MDX-1342

MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 40, 200, 1000, 2000 mg/dose.

Trial Locations (3)

14263

Roswell Park Cancer Institute, Buffalo

77024

Oncology Consultants, PA, Houston

02115

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY